IL292420A - Ornithine transcarbamylase (otc) structures and methods for their use - Google Patents
Ornithine transcarbamylase (otc) structures and methods for their useInfo
- Publication number
- IL292420A IL292420A IL292420A IL29242022A IL292420A IL 292420 A IL292420 A IL 292420A IL 292420 A IL292420 A IL 292420A IL 29242022 A IL29242022 A IL 29242022A IL 292420 A IL292420 A IL 292420A
- Authority
- IL
- Israel
- Prior art keywords
- pct
- otc
- polynucleotide construct
- mrna
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/03—Carboxy- and carbamoyltransferases (2.1.3)
- C12Y201/03003—Ornithine carbamoyltransferase (2.1.3.3)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924567P | 2019-10-22 | 2019-10-22 | |
| PCT/US2020/056890 WO2021081225A1 (en) | 2019-10-22 | 2020-10-22 | Ornithine transcarbamylase (otc) constructs and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292420A true IL292420A (en) | 2022-06-01 |
Family
ID=75620841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292420A IL292420A (en) | 2019-10-22 | 2020-10-22 | Ornithine transcarbamylase (otc) structures and methods for their use |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230001021A1 (https=) |
| EP (1) | EP4048317A4 (https=) |
| JP (1) | JP7826197B2 (https=) |
| KR (1) | KR20240130161A (https=) |
| CN (1) | CN116096428A (https=) |
| AU (1) | AU2020371697A1 (https=) |
| CA (1) | CA3158626A1 (https=) |
| IL (1) | IL292420A (https=) |
| WO (1) | WO2021081225A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| WO2022229903A1 (en) * | 2021-04-28 | 2022-11-03 | Genevant Sciences Gmbh | Mrna delivery constructs and methods of using the same |
| KR20230083893A (ko) * | 2021-12-03 | 2023-06-12 | 고려대학교 산학협력단 | 번역 효율이 향상된 5'-utr, 이를 포함하는 합성 핵산 분자 및 이를 포함하는 백신 또는 치료제 조성물 |
| KR20250169641A (ko) * | 2023-03-06 | 2025-12-03 | 제네럴 메디신스 엘엘씨 | 코돈 최적화 및 이의 사용 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201405157PA (en) | 2012-02-24 | 2014-10-30 | Protiva Biotherapeutics Inc | Trialkyl cationic lipids and methods of use thereof |
| WO2015011633A1 (en) * | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
| EP3027221A1 (en) * | 2013-07-30 | 2016-06-08 | PhaseRx, Inc. | Block copolymers and their conjugates or complexes with oligonucleotides |
| US9765477B2 (en) * | 2013-08-23 | 2017-09-19 | Dow Global Technologies Llc | Low density attached polyurethane foams made using a combination of frothing and blowing methods |
| US11219634B2 (en) * | 2015-01-21 | 2022-01-11 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| CA3027312A1 (en) * | 2016-06-13 | 2017-12-21 | Translate Bio, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
| FI3568483T3 (fi) * | 2017-01-10 | 2025-11-21 | Childrens Medical Res Institute | Polynukleotideja ja vektoreita siirtogeenien ilmentämiseen |
| EP3714048B1 (en) * | 2017-11-22 | 2025-04-09 | ModernaTX, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
-
2020
- 2020-10-22 AU AU2020371697A patent/AU2020371697A1/en active Pending
- 2020-10-22 CA CA3158626A patent/CA3158626A1/en active Pending
- 2020-10-22 WO PCT/US2020/056890 patent/WO2021081225A1/en not_active Ceased
- 2020-10-22 KR KR1020227017024A patent/KR20240130161A/ko active Pending
- 2020-10-22 US US17/771,421 patent/US20230001021A1/en active Pending
- 2020-10-22 CN CN202080089266.1A patent/CN116096428A/zh active Pending
- 2020-10-22 IL IL292420A patent/IL292420A/en unknown
- 2020-10-22 JP JP2022523854A patent/JP7826197B2/ja active Active
- 2020-10-22 EP EP20878326.6A patent/EP4048317A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021081225A1 (en) | 2021-04-29 |
| US20230001021A1 (en) | 2023-01-05 |
| KR20240130161A (ko) | 2024-08-29 |
| JP2022553375A (ja) | 2022-12-22 |
| CA3158626A1 (en) | 2021-04-29 |
| EP4048317A4 (en) | 2023-11-22 |
| AU2020371697A1 (en) | 2022-05-26 |
| EP4048317A1 (en) | 2022-08-31 |
| CN116096428A (zh) | 2023-05-09 |
| JP7826197B2 (ja) | 2026-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292420A (en) | Ornithine transcarbamylase (otc) structures and methods for their use | |
| US12564645B2 (en) | Methods for treatment of methylmalonic acidemia | |
| IL301973A (en) | Improved process of preparing mrna-loaded lipid nanoparticles | |
| CN110446506A (zh) | 具有包封在纳米脂质体中的cas9蛋白、抑制srd5a2基因表达的指导rna和阳离子聚合物之复合物的纳米脂质体-微泡缀合物,以及用于改善或治疗毛发脱落的包含所述纳米脂质体-微泡缀合物的组合物 | |
| IL294073A (en) | Rectal administration of messenger rna | |
| US20210145860A1 (en) | Compositions, methods and uses of messenger rna | |
| KR20140048404A (ko) | 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물 | |
| CN120676970A (zh) | 用于核酸靶向递送的包含升高的天然脂质和靶向部分的脂质纳米颗粒 | |
| IL323452A (en) | In vivo nickase-based editing of the lpa gene for the treatment of cardiovascular diseases | |
| WO2026077273A1 (zh) | 含LNP和mRNA的组合物及其在治疗戈谢病中的应用 | |
| JP2025518221A (ja) | 核酸の送達のための複合体 | |
| US20240216545A1 (en) | Mrna delivery constructs and methods of using the same | |
| NL2033672B1 (en) | Compounds and compositions for delivery of agents to cells | |
| WO2024217406A1 (zh) | 一种表达水通道蛋白AQP3的mRNA及其应用 | |
| US20240316165A1 (en) | Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia | |
| CN120129751A (zh) | 新型分泌信号肽 | |
| US20250312491A1 (en) | Base editing of transthyretin gene | |
| US20240124536A1 (en) | Base editing of transthyretin gene | |
| US20250114478A1 (en) | Lipid nanoparticle (lnp) compositions for brain-selective cargo delivery, and methods of use thereof | |
| US20260035707A1 (en) | Engineered polynucleotides for temporal control of expression | |
| US20250090684A1 (en) | Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a) | |
| US20240269248A1 (en) | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia | |
| EP4683665A1 (en) | Peg targeting compounds for delivery of therapeutics | |
| WO2025226912A1 (en) | Cell-type specific delivery of gene editors and methods of use thereof | |
| US20260014258A1 (en) | Peg targeting compounds for delivery of therapeutics |